ZA200102961B - Method for preparing a solution for nasal spray containing sex hormones and a cyclodextrin. - Google Patents
Method for preparing a solution for nasal spray containing sex hormones and a cyclodextrin. Download PDFInfo
- Publication number
- ZA200102961B ZA200102961B ZA200102961A ZA200102961A ZA200102961B ZA 200102961 B ZA200102961 B ZA 200102961B ZA 200102961 A ZA200102961 A ZA 200102961A ZA 200102961 A ZA200102961 A ZA 200102961A ZA 200102961 B ZA200102961 B ZA 200102961B
- Authority
- ZA
- South Africa
- Prior art keywords
- solution
- cyclodextrin
- oestradiol
- process according
- purified water
- Prior art date
Links
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title claims description 31
- 229920000858 Cyclodextrin Polymers 0.000 title claims description 27
- 238000000034 method Methods 0.000 title claims description 21
- 239000003163 gonadal steroid hormone Substances 0.000 title claims description 11
- 229940097496 nasal spray Drugs 0.000 title claims description 4
- 239000007922 nasal spray Substances 0.000 title claims description 4
- 239000000243 solution Substances 0.000 claims description 45
- 238000002360 preparation method Methods 0.000 claims description 29
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 26
- 229930182833 estradiol Natural products 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 239000008213 purified water Substances 0.000 claims description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- 229940088597 hormone Drugs 0.000 claims description 15
- 239000005556 hormone Substances 0.000 claims description 15
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 239000000583 progesterone congener Substances 0.000 claims description 7
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 6
- 229960001652 norethindrone acetate Drugs 0.000 claims description 6
- 229960003604 testosterone Drugs 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 3
- 150000000319 19-nortestosterones Chemical class 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 14
- 238000004090 dissolution Methods 0.000 description 12
- 239000000186 progesterone Substances 0.000 description 9
- 229960003387 progesterone Drugs 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229940100656 nasal solution Drugs 0.000 description 6
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940053934 norethindrone Drugs 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001616 chlormadinone acetate Drugs 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960001853 demegestone Drugs 0.000 description 1
- JWAHBTQSSMYISL-MHTWAQMVSA-N demegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 JWAHBTQSSMYISL-MHTWAQMVSA-N 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960004913 dydrogesterone Drugs 0.000 description 1
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 1
- 229960000218 etynodiol Drugs 0.000 description 1
- 229960005352 gestodene Drugs 0.000 description 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- -1 laevonorgestrel Chemical compound 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960000606 medrogestone Drugs 0.000 description 1
- HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229960004190 nomegestrol acetate Drugs 0.000 description 1
- IIVBFTNIGYRNQY-YQLZSBIMSA-N nomegestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 IIVBFTNIGYRNQY-YQLZSBIMSA-N 0.000 description 1
- 229960000417 norgestimate Drugs 0.000 description 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
- 150000003128 pregnanes Chemical class 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 229960001584 promegestone Drugs 0.000 description 1
- QFFCYTLOTYIJMR-XMGTWHOFSA-N promegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)CC)(C)[C@@]1(C)CC2 QFFCYTLOTYIJMR-XMGTWHOFSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9812836A FR2784584B1 (fr) | 1998-10-14 | 1998-10-14 | Procede de preparation d'une solution pour pulverisation nasale contenant une ou plusieurs hormones sexuelles et une cyclodextrine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200102961B true ZA200102961B (en) | 2001-11-20 |
Family
ID=9531516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200102961A ZA200102961B (en) | 1998-10-14 | 2001-04-10 | Method for preparing a solution for nasal spray containing sex hormones and a cyclodextrin. |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1121100B1 (enExample) |
| JP (1) | JP3911125B2 (enExample) |
| KR (1) | KR100462441B1 (enExample) |
| CN (1) | CN1323198A (enExample) |
| AT (1) | ATE237310T1 (enExample) |
| AU (1) | AU756441B2 (enExample) |
| BR (1) | BR9914532A (enExample) |
| CA (1) | CA2346567C (enExample) |
| DE (1) | DE69907005T2 (enExample) |
| DK (1) | DK1121100T3 (enExample) |
| EA (1) | EA003069B1 (enExample) |
| ES (1) | ES2197672T3 (enExample) |
| FR (1) | FR2784584B1 (enExample) |
| HK (1) | HK1040201A1 (enExample) |
| HU (1) | HUP0103968A3 (enExample) |
| NO (1) | NO20011673L (enExample) |
| NZ (1) | NZ510776A (enExample) |
| PL (1) | PL347322A1 (enExample) |
| PT (1) | PT1121100E (enExample) |
| WO (1) | WO2000021503A1 (enExample) |
| ZA (1) | ZA200102961B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2827516B1 (fr) * | 2001-07-19 | 2003-09-19 | Servier Lab | Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone |
| JPWO2005018607A1 (ja) * | 2003-08-20 | 2007-11-01 | 味の素株式会社 | 溶解性を改善した医薬品製剤 |
| GB2482868A (en) * | 2010-08-16 | 2012-02-22 | Franciscus Wilhelmus Henricus Maria Merkus | A testosterone liquid spray formulation for oromucosal administration |
| MX2014004202A (es) * | 2011-10-07 | 2015-03-05 | Univ Florida State Res Found | Uso post-agudo y profiláctico de progesterona para mejores resultados asociados con concusión. |
| RU2623066C2 (ru) | 2012-01-20 | 2017-06-21 | Аратана Терапьютикс Нв | Композиция глазных капель |
| RU2753511C2 (ru) * | 2017-05-31 | 2021-08-17 | Аратана Терапьютикс, Инк. | Композиция глазных капель |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8801670A (nl) * | 1988-07-01 | 1990-02-01 | Walter Adrianus Josephus Johan | Farmaceutisch preparaat. |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9012663D0 (en) * | 1990-06-07 | 1990-08-01 | Erba Carlo Spa | Galenic formulations containing cyclodextrins |
| DE4207922A1 (de) * | 1992-03-13 | 1993-09-23 | Pharmatech Gmbh | Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung |
| BE1007402A5 (nl) * | 1993-03-26 | 1995-06-06 | Adir | Nasale farmaceutische preparaten met progestagene stof. |
-
1998
- 1998-10-14 FR FR9812836A patent/FR2784584B1/fr not_active Expired - Fee Related
-
1999
- 1999-10-13 HK HK02102010.0A patent/HK1040201A1/zh unknown
- 1999-10-13 KR KR10-2001-7004679A patent/KR100462441B1/ko not_active Expired - Fee Related
- 1999-10-13 ES ES99947567T patent/ES2197672T3/es not_active Expired - Lifetime
- 1999-10-13 JP JP2000575479A patent/JP3911125B2/ja not_active Expired - Fee Related
- 1999-10-13 DK DK99947567T patent/DK1121100T3/da active
- 1999-10-13 AT AT99947567T patent/ATE237310T1/de not_active IP Right Cessation
- 1999-10-13 NZ NZ510776A patent/NZ510776A/xx unknown
- 1999-10-13 BR BR9914532-4A patent/BR9914532A/pt not_active Application Discontinuation
- 1999-10-13 HU HU0103968A patent/HUP0103968A3/hu unknown
- 1999-10-13 CA CA002346567A patent/CA2346567C/fr not_active Expired - Fee Related
- 1999-10-13 DE DE69907005T patent/DE69907005T2/de not_active Expired - Fee Related
- 1999-10-13 PT PT99947567T patent/PT1121100E/pt unknown
- 1999-10-13 WO PCT/FR1999/002480 patent/WO2000021503A1/fr not_active Ceased
- 1999-10-13 CN CN99812123A patent/CN1323198A/zh active Pending
- 1999-10-13 AU AU60967/99A patent/AU756441B2/en not_active Ceased
- 1999-10-13 EA EA200100316A patent/EA003069B1/ru not_active IP Right Cessation
- 1999-10-13 EP EP99947567A patent/EP1121100B1/fr not_active Expired - Lifetime
- 1999-10-13 PL PL99347322A patent/PL347322A1/xx unknown
-
2001
- 2001-04-03 NO NO20011673A patent/NO20011673L/no not_active Application Discontinuation
- 2001-04-10 ZA ZA200102961A patent/ZA200102961B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69907005T2 (de) | 2004-03-18 |
| CA2346567C (fr) | 2005-06-14 |
| AU6096799A (en) | 2000-05-01 |
| CN1323198A (zh) | 2001-11-21 |
| EP1121100B1 (fr) | 2003-04-16 |
| NO20011673D0 (no) | 2001-04-03 |
| CA2346567A1 (fr) | 2000-04-20 |
| EA003069B1 (ru) | 2002-12-26 |
| DE69907005D1 (de) | 2003-05-22 |
| JP3911125B2 (ja) | 2007-05-09 |
| DK1121100T3 (da) | 2003-07-21 |
| HK1040201A1 (zh) | 2002-05-31 |
| WO2000021503A1 (fr) | 2000-04-20 |
| FR2784584A1 (fr) | 2000-04-21 |
| ES2197672T3 (es) | 2004-01-01 |
| HUP0103968A2 (hu) | 2002-04-29 |
| PT1121100E (pt) | 2003-07-31 |
| FR2784584B1 (fr) | 2002-09-20 |
| NO20011673L (no) | 2001-04-03 |
| EP1121100A1 (fr) | 2001-08-08 |
| NZ510776A (en) | 2002-10-25 |
| KR100462441B1 (ko) | 2004-12-17 |
| ATE237310T1 (de) | 2003-05-15 |
| JP2002527374A (ja) | 2002-08-27 |
| AU756441B2 (en) | 2003-01-16 |
| PL347322A1 (en) | 2002-03-25 |
| EA200100316A1 (ru) | 2002-02-28 |
| HUP0103968A3 (en) | 2002-06-28 |
| BR9914532A (pt) | 2001-11-06 |
| KR20010073214A (ko) | 2001-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5089482A (en) | Pharmaceutical compositions for nasal administration containing steroid hormones and dimethyl-β-cyclodextrin | |
| US5955454A (en) | Nasal pharmaceutical composition containing a progestogen | |
| JP2004518656A5 (enExample) | ||
| JPH054924A (ja) | 徐放製剤 | |
| KR20080091156A (ko) | 입에 사용하기 위한 막 형상의 제약 형태 〔웨이퍼〕 | |
| HU181703B (en) | Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents | |
| JPH10511364A (ja) | 安定なブデゾナイド溶液、その製造方法並びに該溶液を浣腸剤及び医薬泡沫剤として使用する用途 | |
| JPH09508912A (ja) | 性ステロイドを含有する経皮治療系 | |
| HU230162B1 (hu) | Fulvesztrantot tartalmazó gyógyászati készítmény | |
| JPH07309762A (ja) | エストロゲンおよび／またはプロゲストゲン投与用エチレン／酢酸ビニルベース経皮マトリックスシステム | |
| KR20100117603A (ko) | 안정화 효과를 갖는 약물 전달 시스템 | |
| AU756441B2 (en) | Method for preparing a solution for nasal spray containing sex hormones and a cyclodextrin | |
| CA3157999A1 (en) | Injectable compositions of ursodeoxycholic acid | |
| JPS62205024A (ja) | エストロゲン欠乏症治療用組成物 | |
| MXPA01003410A (en) | Method for preparing a solution for nasal spray containing sex hormones and a cyclodextrin | |
| JPH04505018A (ja) | 水性混合ミセル溶液を製造する方法 | |
| JPH11130660A (ja) | 鼻腔内投与用水性懸濁製剤 | |
| EP0409936B1 (de) | Verfahren zur herstellung wässriger mischmicellösungen | |
| AU2002336141B2 (en) | Pharmaceutical composition for nasal delivery of estradiol and norethisterone | |
| CN109381424A (zh) | 稳定的黄体酮水溶注射剂及其制备方法 | |
| JPS59116212A (ja) | インドメタシン外用クリ−ム剤およびその製法 | |
| JP3883204B2 (ja) | 低用量薬剤学的製剤の調製方法 | |
| KR20010102464A (ko) | 바람직하지 않은 자궁 출혈을 치료하는데 유용한 비약제조성물을 수득하기 위한 성호르몬의 용도 |